In the News
Alzheimer’s Patients Saluted for Dedication to Drug Trials
GAP-Net site Okanagan Clinical Trials in Kelowna, BC recognized three of its Citizen Scientist Awards nominees in a ceremony at the Okanagan Innovation Centre in downtown Kelowna. A dozen times over two years, Gary Millward and his wife, Debra, drove from Quesnel to Kelowna through everything from wildfires and winter storms to rain and brilliant […]
Global Alzheimer’s Platform Foundation Honors More Than 100 Clinical Trial Participants During National Citizen Scientist Week.
During National Citizen Scientist Week, June 17-21, GAP Honors More Than 100 Award Nominees Washington, DC (June 17, 2019) – June 17-21, 2019 is the first ever National Citizen Scientist Week, a time to honor people who volunteer for Alzheimer’s research and inspire hope for new therapies for the disease. To celebrate the contributions of the remarkable volunteers […]
Alzheimer’s Disease: Risk Factors, Treatments and More
A podcast discussing Alzheimer’s disease – research, risk prevention, and other related topics. Robert Herriman is joined by Phil Sabel, M.A., the Clinical Research Coordinator at GAP-Net site Axiom Clinical Research in Tampa. Click here to listen to the June 13, 2019 episode.
Is an Alzheimer’s Cure on the Horizon?
By the time I was old enough to ask my grandmother questions about her life, it was too late. All I had were skeletons of stories I heard from my mom. I knew that it had been difficult for my grandmother when her parents, Irish immigrants on the vaudeville circuit, left her behind to help […]
8 Ways to Reduce Your Risk of Alzheimer’s (and Maybe Help Researchers Find a Cure Faster)
The threat of Alzheimer’s disease looms over an aging America, but could a cure be in the offing? And if so, how soon? Experts say the answer is “yes” — and by the year 2025. That’s the date they’re shooting for, anyway. Much as President Kennedy once vowed to send a man to the moon […]
Global Alzheimer’s Platform Foundation Commends National Institute on Aging for Advancing Its 2025 Goal by Funding a Diversified Portfolio of Studies
NIA Makes $9 Million Multiyear Grant to Study New Therapeutic Approach, an Orally- Administered Treatment for Alzheimer’s Washington, DC (May 20, 2019) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, today issued the following statement: “The nearly six million Americans with Alzheimer’s and their families deserve for no scientific stone to go […]
Dr. Anna Burke Named 2019 Healthcare Innovator of the Year
AzBusiness recognized Dr. Anna Burke as its 2019 Healthcare Innovator of the Year for her work in treating the behavioral and psychiatric disturbances that result from Alzheimer’s disease as well as her work building a community outreach program in the Phoenix area to teach people about brain health, Alzheimer’s, and clinical research. Dr. Burke is […]
When It Comes to Alzheimer’s, Important Changes Are Coming for MA Beneficiaries
The majority of experts agree that because Alzheimer’s disease is significantly underdiagnosed and underreported, a large number of people may not know they have it. We have both spoken at length about the importance of early detection and diagnosis to allow for earlier interventions and care planning along with a broad array of methods and […]
Global Alzheimer’s Platform Foundation Commends Commissioner Seema Verma and CMS for New Medicare Advantage Benefits and Payment Policies That Will Improve the Care Of Beneficiaries At Risk For Alzheimer’s and Related Dementias
Washington, DC (April 10, 2019) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, today issued the following statement: “The Global Alzheimer’s Platform Foundation thanks Commissioner Seema Verma and the Centers for Medicare and Medicaid Services (CMS) for its thoughtful and impactful leadership in implementing policies that will improve Medicare Advantage beneficiaries’ ability […]
Alzheimer’s Disease Trials: Where Do We Go From Here?
The Alzheimer’s disease space is not an easy one for pharma companies to navigate. In 2018 alone, Lundbeck, Takeda, Merck, Janssen, AstraZeneca, and Eli Lilly and Company all faced setbacks or poor trial results. In March 2019, we learned that Biogen and Eisai also terminated late-phase studies. Fortune magazine notes few spaces in the life […]